Weidenfeld J, Feldman S
Department of Neurology, Hadassah University Hospital, Jerusalem, Israel.
Brain Res. 1991 Mar 1;542(2):201-4. doi: 10.1016/0006-8993(91)91567-k.
In this study we examined the role of the noradrenergic innervation of the hypothalamus on the adrenalectomy-induced changes in median eminence (ME) CRF-41 and serum ACTH. 6-Hydroxydopamine (6-OHDA), the catecholaminergic neurotoxin, or vehicle was injected into the ventral noradrenergic bundle of male rats. One week later animals underwent adrenalectomy or sham operation and were sacrificed 18 or 120 h later. In sham-operated rats 6-OHDA did not affect ME CRF-41 content or serum ACTH. In vehicle-injected adrenalectomized rats ACTH was increased approximately 3-fold at 18 h and almost 6-fold at 120 h. At 18 h CRF-41 content was markedly depleted (reduced approximately 20-fold) but by 120 h CRF-41 content had partially recovered and was about 70% of control animals. In adrenalectomized animals, 6-OHDA lesions caused a complete inhibition of the increase in serum ACTH both at 18 h and at 120 h. Pretreatment with 6-OHDA partially attenuated the drastic reduction in ME CRF-41 content following adrenalectomy at 18 h. However, at 120 h, the neurotoxin prevented the recovery of CRF-41 following adrenalectomy. These results suggest that intact norepinephrine innervation to the hypothalamus is necessary for the increased production of ACTH following adrenalectomy and that its interruption interferes with both the adrenalectomy-induced ME CRF-41 reduction and subsequent recovery.
在本研究中,我们检测了下丘脑去甲肾上腺素能神经支配在肾上腺切除诱导的正中隆起(ME)促肾上腺皮质激素释放因子(CRF)-41和血清促肾上腺皮质激素(ACTH)变化中的作用。将儿茶酚胺能神经毒素6-羟基多巴胺(6-OHDA)或赋形剂注入雄性大鼠的腹侧去甲肾上腺素能束。一周后,动物接受肾上腺切除术或假手术,并在18或120小时后处死。在假手术大鼠中,6-OHDA不影响ME CRF-41含量或血清ACTH。在注射赋形剂的肾上腺切除大鼠中,ACTH在18小时时增加约3倍,在120小时时增加近6倍。在18小时时,CRF-41含量明显减少(减少约20倍),但到120小时时,CRF-41含量已部分恢复,约为对照动物的70%。在肾上腺切除动物中,6-OHDA损伤在18小时和120小时均导致血清ACTH升高的完全抑制。用6-OHDA预处理可部分减轻肾上腺切除术后18小时ME CRF-41含量的急剧降低。然而,在120小时时,神经毒素阻止了肾上腺切除术后CRF-41的恢复。这些结果表明,下丘脑完整的去甲肾上腺素能神经支配对于肾上腺切除术后ACTH的增加产生是必需的,并且其中断会干扰肾上腺切除诱导的ME CRF-41减少和随后的恢复。